Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Andrew W Roberts

Showing results (101-110 of 198) with videos related to

Pageof 20
Sort By:
Pathology|August 19, 2006
Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral bloodWilliam S Stevenson, Rosemary Hoyt, Anthony Bell, et al.
Immunology and Cell Biology|April 27, 2011
IL-6 promotes acute and chronic inflammatory disease in the absence of SOCS3Ben A Croker, Hiu Kiu, Marc Pellegrini, et al.
Ejhaem|July 18, 2022
Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapySasanka Handunnetti, Mary Ann Anderson, Andrew W Roberts, et al.
Blood|May 6, 2017
Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclaxMary Ann Anderson, Constantine Tam, Thomas E Lew, et al.
EMBO Reports|July 3, 2010
Regulation of interleukin-1beta by interferon-gamma is species specific, limited by suppressor of cytokine signalling 1 and influences interleukin-17 productionSeth L Masters, Lisa A Mielke, Ann L Cornish, et al.
Blood|April 4, 2020
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclaxVictor S Lin, Thomas E Lew, Sasanka M Handunnetti, et al.
Blood Advances|May 28, 2025
Emergent BAX-mutated clonal hematopoiesis after venetoclax-based therapy for breast cancerIng S Tiong, Tamia Nguyen, Chong C Chua, et al.
Blood Advances|January 15, 2020
Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 monthsThomas E Lew, Mary Ann Anderson, Victor S Lin, et al.
Blood Advances|October 8, 2020
Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapyJoanne E Davis, Sasanka M Handunnetti, Mandy Ludford-Menting, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 26, 2006
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimeticJunya Kuroda, Hamsa Puthalakath, Mark S Cragg, et al.
Pageof 20

Showing results (101-110 of 198) with videos related to

Sort By:
Pageof 20
Pathology|August 19, 2006
Genetic heterogeneity of granulocytes for the JAK2 V617F mutation in essential thrombocythaemia: implications for mutation detection in peripheral bloodWilliam S Stevenson, Rosemary Hoyt, Anthony Bell, et al.
Immunology and Cell Biology|April 27, 2011
IL-6 promotes acute and chronic inflammatory disease in the absence of SOCS3Ben A Croker, Hiu Kiu, Marc Pellegrini, et al.
Ejhaem|July 18, 2022
Addition of rituximab in relapsed/refractory chronic lymphocytic leukemia after progression on venetoclax monotherapySasanka Handunnetti, Mary Ann Anderson, Andrew W Roberts, et al.
Blood|May 6, 2017
Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclaxMary Ann Anderson, Constantine Tam, Thomas E Lew, et al.
EMBO Reports|July 3, 2010
Regulation of interleukin-1beta by interferon-gamma is species specific, limited by suppressor of cytokine signalling 1 and influences interleukin-17 productionSeth L Masters, Lisa A Mielke, Ann L Cornish, et al.
Blood|April 4, 2020
BTK inhibitor therapy is effective in patients with CLL resistant to venetoclaxVictor S Lin, Thomas E Lew, Sasanka M Handunnetti, et al.
Blood Advances|May 28, 2025
Emergent BAX-mutated clonal hematopoiesis after venetoclax-based therapy for breast cancerIng S Tiong, Tamia Nguyen, Chong C Chua, et al.
Blood Advances|January 15, 2020
Undetectable peripheral blood MRD should be the goal of venetoclax in CLL, but attainment plateaus after 24 monthsThomas E Lew, Mary Ann Anderson, Victor S Lin, et al.
Blood Advances|October 8, 2020
Immune recovery in patients with mantle cell lymphoma receiving long-term ibrutinib and venetoclax combination therapyJoanne E Davis, Sasanka M Handunnetti, Mandy Ludford-Menting, et al.
Proceedings of the National Academy of Sciences of the United States of America|September 26, 2006
Bim and Bad mediate imatinib-induced killing of Bcr/Abl+ leukemic cells, and resistance due to their loss is overcome by a BH3 mimeticJunya Kuroda, Hamsa Puthalakath, Mark S Cragg, et al.
Pageof 20